Trial Profile
Real World Experience of Chronic Hepatitis C Treatment in Israeli Patients With Advanced Liver Fibrosis With Fixed Dose Combination (FDC) Grazoprevir (100 mg)/Elbasvir (50mg) (Zepatier) ± Ribavirin: A Retrospective Multicenter Cohort Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin (Primary)
- Indications Fibrosis; Hepatitis C
- Focus Therapeutic Use
- 30 Jan 2023 Status changed from active, no longer recruiting to completed.
- 23 Jul 2018 Planned number of patients changed from 100 to 700.
- 23 Jul 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2020.